This study is being conducted to confirm the efficacy, safety, and immunogenicity of recombinant human C1 inhibitor (rhC1INH) at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in Hereditary Angioedema (HAE) patients.
HAE is characterized by recurrent localized angioedema caused by uncontrolled activation of the complement and contact systems due to a congenital deficiency of functional C1 inhibitor. rhC1INH has been developed to offer a more widely available therapeutic alternative to the existing plasma-derived C1INH (pdC1INH) products that have been used in the treatment of acute angioedema attacks patients with HAE. Patients who have qualified for enrollment in advance and who present to a study center within 5 hours of onset of an attack will be evaluated for eligibility. 75 eligible patients will be randomized (3:2) to receive an intravenous infusion of rhC1INH or saline in a double-blind fashion. Open-label rhC1INH may be provided as rescue medication to patients who do not experience the beginning of relief within 4 hours or who experience life-threatening oropharyngeal-laryngeal angioedema symptoms. Any patient having received a randomized treatment will be allowed to receive treatment with rhC1INH in an open-label fashion for subsequent eligible attacks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
75
One i.v. injection of rhC1INH at the dose of 50 U/kg, for patients up to 84 kg; one i.v. injection of rhC1INH at the dose of 4200U (2 vials) for patients of 84 kg body weight or greater.
One i.v. injection of saline (NaCl 0.9% w/v), equivalent in volume to the active treatment
Time to Beginning of Relief of Symptoms
Time to beginning of relief is the time lapsed from the beginning of the infusion of study medication to the beginning of a beneficial effect based on patient's responses to the Treatmetn Effect Questionnaire (TEQ) for the primary attack location. The beginning of relief is defined as the first timepoint at which * The patient reports any of the following answers for TEQ question 1: "A little better", "Better" or "Much better"; and; * The patient reports the following answer for TEQ question 2: "Yes"; and, * There is persistence in improvement at the next assessment time, i.e.either the same or a better response to Question 1 and "Yes" to Question 2.
Time frame: Patients observed for 24 hours
Time to Minimal Symptoms
The key secondary efficacy endpoint was the time to minimal symptoms at all locations. The time to achieving minimal symptoms was defined as an answer of "Yes" to TEQ question 3.
Time frame: 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Allergy, Asthma & Immunology, Assoc, Ltd.
Scottsdale, Arizona, United States
Allergy and Asthma Institute of the Valley
Granada Hills, California, United States
UCLA Department of Medicine Division of Clinical Immunology, David Geffen School of Medicine
Los Angeles, California, United States
USF Asthma, Allergy and Immunology Clinical Research Unit
Tampa, Florida, United States
Family Allergy and Asthma Center
Atlanta, Georgia, United States
Institute for Asthma and Allergy, P.C.
Chevy Chase, Maryland, United States
Asthma & Allergy Center - Washington University School of Medicine
St Louis, Missouri, United States
University of Cincinnati Physicians, Inc.
Cincinnati, Ohio, United States
Optimed Research, LTD
Columbus, Ohio, United States
Baker Allergy, Asthma and Dermatology Research Center, LLC
Lake Oswego, Oregon, United States
...and 17 more locations